Results 1 to 10 of about 28,157 (212)

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers [PDF]

International Journal of Infectious Diseases, 2022
Objectives: There are limited comparative immunologic durability data post COVID-19 vaccinations. Methods: Approximately 8.4 months after primary COVID-19 vaccination, 647 healthcare workers completed surveys about COVID-19 vaccinations/infections and ...
Wendy M. Brunner, Daniel Freilich, Jennifer Victory, Nicole Krupa, Melissa B. Scribani, Paul Jenkins, Emily G. Lasher, Amanda Fink, Anshini Shah, Peggy Cross, Valerie Bush, Laura J. Peek, Gary A. Pestano, Anne M. Gadomski   +13 more
doaj   +2 more sources

Effectiveness of COVID-19 Vaccination in Reducing Severity Among SARS-CoV-2 Infected Patients: A Prospective Study From Iraq. [PDF]

Health Sci Rep
ABSTRACT Background Coronavirus disease 2019 (COVID‐19) is a lethal global pandemic that originated in Wuhan, China at the end of 2019. As with other viral infectious diseases, the introduction of an effective vaccine is crucial for stopping the spread of the pandemic. In Iraq the COVID‐19 vaccination campaign started on March 2, 2021.
Al-Obaidi AH, Ibrahim MM, Al-Qaseer AHAM.   +2 more
europepmc   +2 more sources

Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil [PDF]

BMJ Public Health
Objectives To compare antispike IgG levels over a period of 182 days of follow-up in healthy adults who received full or fractional booster doses of BNT162b2 or AZD1222 after completing a primary series of Sinovac, BNT162b2 or AZD1222.Design Double-blind,
Haley Hedlin, Vivek Charu, Di Lu, Patricia Vieira da Silva, Julio Croda, Amy Zhang, Farah Qamar, Joelle I Rosser, Juliana Barros Verruck, Marco Antonio Moreira Puga, Roberto Dias de Oliveira, Victor Ritter, Blake Shaw, Jessica Couvillion Seidman, Alice Scott Carter, Stephen Luby, Denise Garrett   +16 more
doaj   +2 more sources

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting [PDF]

Scientific Reports
This 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID 
Aini Syahida Mat Yassim, Anis Atifah Mohd Hisham, Nik Nur Atiqah Nik Daud, Nur Diana Anuar, Ti-Myen Tan, Rapeah Suppian, Mat Jusoh Siti Asmaa, Amiratul Aifa Mohamad Asri, Maryam Azlan, Nur Suhaila Idris, Rosediani Muhamad, Mohd Nor Norazmi   +11 more
doaj   +2 more sources

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2023
Introduction/Objective. The duration of vaccine-induced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant ...
Đorđević Nataša, Matić Sanja, Milovanović Dragan, Stefanović Srđan, Popović Suzana, Todorović Danijela, Đurđević Predrag, Sazdanović Predrag, Antić Vasilije, Lončar Slavica, Bukumira Slavica, Radenković Marko, Šusteršić Tijana, Filipović Nenad, Baskić Dejan   +14 more
doaj   +1 more source

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial [PDF]

Infectious Diseases and Therapy
Introduction COVID-19 continues to cause substantial health burden, particularly among vulnerable populations. Vaccines remain a vital tool in preventing severe disease outcomes. As the causative pathogen, severe acute respiratory syndrome coronavirus 2 (
Oyeniyi Diya, Juleen Gayed, Francine S. Lowry, Hua Ma, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Mark Cutler, Todd Belanger, David Cooper, Xia Xu, Robin Mogg, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin   +20 more
doaj   +2 more sources

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

Human Vaccines & Immunotherapeutics, 2023
Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable ...
Moe H. Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh, Amit Srivastava   +4 more
doaj   +1 more source

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination

Vaccines, 2023
Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in ...
Kevin D. Dieckhaus, Min-Jung Kim, Jian-Bing Shen, Tina S. Liang, Michael J. Kleinberg, Kristen M. Siedlarz, David B. Banach, Mark L. Metersky, Rob P. Fuller, Eric M. Mortensen, Bruce T. Liang   +10 more
doaj   +1 more source

Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents. [PDF]

Pediatr Infect Dis J
Gwak E, Choe SA, Kim K, Bolormaa E, Gschwend MH, Fix J, Vadivale M, Rousculp MD, Choe YJ.   +8 more
europepmc   +3 more sources

Granulomatous anterior uveitis following mRNA-based COVID-19 vaccination: A case report

Indian Journal of Ophthalmology, 2023
A 23-year-old patient presented with complaints of redness, pain, photophobia, and blurred vision in the right eye 15 days after she received the third dose of BNT162b2 vaccination.
Furkan Cam, Gizem Gok, Hande Celiker
doaj   +1 more source